IRCT20200127046282N35
Not yet recruiting
Phase 1
Investigating the safety and efficacy of intradermal stromal vascular fraction cells injection of autologous fat tissue in patients with scleroderma (clinical, biometric and laboratory evaluation): Phase I and II clinical study
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- scleroderma.
- Sponsor
- Tehran University of Medical Sciences
- Enrollment
- 18
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The patient is suffering from scleroderma and has been diagnosed by a doctor.
- •The patient has skin involvement in the fingers or face.
- •The patient is in the stable phase of the disease, which is confirmed by the attending physician.
- •The patient has the desire to perform the mentioned procedure.
Exclusion Criteria
- •having infectious diseases.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 1
Investigating nanofat injection and conditioned medium derived from stem cells in the treatment of androgenic alopeciaHair loss.Nonscarring hair loss, unspecifiedL65.9IRCT20200127046282N34Tehran University of Medical Sciences10
Not yet recruiting
Phase 2
Facial Pigmentation Treatment by Injection Tranexamic acid intradermally in skiHealth Condition 1: L811- ChloasmaCTRI/2022/02/040450Dr Meghna Khatri
Not yet recruiting
Phase 1
Assessment of the effect of exosomes in the treatment of melasmaIRCT20221130056672N6Tehran University of Medical Sciences30
Not yet recruiting
Not Applicable
Comparative study of Intradermal versus Intralesional Purified Protein Derivative (PPD) for treatment of common warts in childreHealth Condition 1: L088- Other specified local infections of the skin and subcutaneous tissueCTRI/2019/07/020070Himachal Pradesh University
Recruiting
Not Applicable
A study to compare efficacy of intradermal Tranexamic acid injections versus topical Tranexamic acid gel versus topical triple combination (Hydroquinone 2 %, Tretinion 0.025%, Flucinolone acetonide 0.01%) cream in patients suffering from melasmaCTRI/2017/07/009158MGM Medical COllege and Hospital180